GSK3174998 is being investigated in combination with other anticancer agents in multiple tumor types, Linch SN, McNamara MJ, Redmond WL. Bell CF, et al. Patient Perceptions of Treatment Success in Uncomplicated Urinary Tract Infection. Silver J, Bogart M, Molfino N, et al. 4. Causes of Death in Patients with Anemia of ?Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial. 2017;130(suppl 1): 1377. Niraparib is a selective PARP1/2 inhibitor approved as monotherapy for the maintenance treatment of adult patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. We're taking on some of the biggest healthcare challenges in . Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. A real-world assessment of patients with ovarian cancer who received niraparib first-line maintenance therapy in the United States. Benefits of Initiating Single-Inhaler Triple Therapy (SITT) with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Multiple-Inhaler Triple Therapy (MITT) Among Medicare Advantage with Part D Beneficiaries with Chronic Obstructive Pulmonary Disease (COPD). PO2409, ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. Kerwin EM, Bjermer L, Maltais F, et al. CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial. ENCORE: Safety and activity of autologous T cells with enhanced NY-ESO-1?specific T-cell receptor (GSK3377794) in HLA-a*02+ previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-E), 19. Partner closely with MOC, medical affairs managers and 3rd party agencies to drive timely plan execution. 6. Visit 7. Brain Metastases in Primary Ovarian Cancer: Real-world Data, 1. Averell CM, Hahn BA, Zografos L, et al. POSTER: Frequency and impact of retreatment in relapsed refractory multiple myeloma (RRMM): Real-world survey conducted in 5 European Countries (United Kingdom, France, Germany, Italy, Spain), 3. Gsk Medical Affairs Jobs - 2022 | Indeed.com Start of main content What Date posted Posted By Remote Salary estimate Job type Education level Industry Location Company Post your resume and find your next job on Indeed! Front Immunol. The results included enhanced training for recruiting managers, a thorough review of job postings and more direction on the channels used to reach and attract candidates. Poster No. Cho S-F, Anderson KC, Tai Y-T. Communication with Patients/Parents on MenB Vaccination for Older Adolescents and Young Adults. Baseline Platelet Count and Body Weight as Predictors of Early Dose Modification in the QUADRA Trial of Niraparib Monotherapy for the Treatment of Heavily Pretreated (?4th Line), Advanced, Recurrent High Grade Serous Ovarian Cancer, 4. Get notified about new Gsk Medical Affairs jobs in United States. Onze 2018;22(4):343-351. Aydanos a proteger Glassdoor verificando que eres una persona real. POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM](Encore), 6. Singh T et al. 4. POSTER: ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC), 3. GSK. takebackday.dea.govw Si continas viendo este mensaje, Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Findings From the Macunama Study, 5. Bogart M, Chastek B, White J, et al. 3. Davitte J, DeBarmore B, Hinds D, et al. 1-800-FDA-1088 You may also report suspected adverse reactions to the FDA at Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-analysis, 10. Current real-world treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma, 2. Find out more: gsk.to/41zwzb7, While everyone can be impacted by #myelofibrosis, certain risk factors can increase the likelihood that a person will develop it. #ppswgw#myoldmedsd#safestorageg#safedisposaladH. Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations. Bogart M, Bengtson L, Rothnie K, et al. Ismaila A, Haeussler K, Czira A, et al. Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea. Bogart M, Han X, Bengtson L, et al. Abstract Publication No. POSTER: Management of immune-related adverse events in patients with solid tumours treated with dostarlimab in the GARNET study (IGCS ENCORE), 1.POSTER: AGO-OVAR 28 / ENGOT-ov57: Niraparib vs niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial) (Presentation Posted With Permission), 2.POSTER: Characterization of long term survivor and maintenance therapy in relapsed ovarian cancer (CAROLIN)- Intergroup study NOGGO / A-AGO (Presentation Posted With Permission), 3.POSTER: Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) (Presentation Posted With Permission), 1. If not, try adjusting your search terms or contact GSK Medical Information at 1-877-GSK-MI4U (1-877-475-6448) Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial? Assessment of Asthma Control in Respiratory Specialist Offices in the US. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. Insights From Allergy Practice. 1. 12. All rights reserved. Real-World Impact of Systemic Corticosteroid (SCS) Exposure on Healthcare Resource Utilization (HRU) due to SCS-Related Complication among Patients with Asthma in the US? Bell CF, Blauer-Peterson C. McCormack E, Adams KJ, Hassan NJ, et al. 12. ORAL PRESENTATION: Pharmacodynamic Effect of Sequential Belimumab and Rituximab Therapy in Patients with SLE: BLISS-BELIEVE Study, 1. Lamentamos Patient Profiles in Eosinophilic Granulomatosis With Polyangiitis (EGPA) ? 4. 2017;3(4):294-301. Expert Opin Ther Targets. Step-up to High Dose Fluticasone Furoate in Combination With Long-Acting Bronchodilator in Inadequately Controlled Asthma: The CAPTAIN Study. 1. 1. The anti-tumor efficacy of TIM-3 blockade in a murine model of sarcoma, 1. A Prospective Evaluation of Tolerability of Niraparib Dosing Based Upon Baseline Body Weight and Platelet Count: Blinded Pooled Interim Safety Data From the PRIMA/ENGOT OV26/GOG 3012 Study, 3. Patients? 4. ORAL PRESENTATION: Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER), 3. POSTER: Antitumor activity and safety of dostarlimab therapy in patients with endometrial cancer by age subgroups: a post-hoc analysis from the GARNET trial, 2. Quick Links Grants Compassionate Use Investigator Sponsored Studies GSK study Register (Clinical Trial Data and Trial Recruitment) Oncohematology POSTER: Meta-analysis of pazopanib and trabectedin in 2L+ metastatic synovial sarcoma (2L+ mSS), 5. You are using an unsupported browser.Some features of this site may not function properly. A Population Study. We also share information about your use of our site with our advertising, social media and analytics partners. POSTER: Differentiation of Niraparib and Olaparib Brain Penetration in a Mouse Brain Metastatic Tumor, 4. Strobel MJ, Alves D, Roufosse F, et al. Requena, G et al. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. GSK?S SCIENTIFIC ACTIVITIES AT IDWEEK 2020, 2. 14. 2. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. enva un correo electrnico a Kovalszki A, Wechsler M, Silver J, et al. Ajude-nos a manter o Glassdoor seguro confirmando que voc uma pessoa de 60 ), 2. GSK6097608 inhibits the binding of CD96 to CD155 and activates T cells and NK cells, which enhances antitumor activity. 2. 3888792. 714; Abstract A4267]. Intramuscular Sotrovimab is Noninferior to Intravenous Sotrovimab For COVID-19, 1. Identifying drivers of patients? ORAL PRESENTATION: Non-OS endpoints in oncology: strategies to bridge the gap in value attribution by regulators, payors, oncologists, and patients, 1. ORAL PRESENTATION: Corneal Ulcers/Erosions in Patients Treated with Belantamab Mafodotin, 1. Effect of Serostatus on the Efficacy of Sotrovimab in Preventing COVID-19 Progression, 2. 2017;47(5):765-779. POSTER: Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in patients with recurrent ovarian cancer, 3. 2001-2023 GSK plc. 5. GSK Solid Tumor Oncology Account Manager; Long Island East, NY Long Island-Queens 30d+ $160K-$216K Per Year (Employer est.) This medical information is intended only for healthcare professionals registered to practice in the United States and is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-? Poster No. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study. Gsk Medical jobs in London Sort by: relevance - date Page 1 of 116 jobs new Medical Scientific Liaison - Specialty/Rheumatology Team Bui. PUBLICATION ONLY: STING Agonist GSK3745417 Induces Apoptosis, Antiproliferation, and Cell Death in a Panel of Human AML Cell Lines and Patient Samples, 1.POSTER: Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network (Presentation Posted With Permission), 2. Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients With Chronic Obstructive Pulmonary Disease (COPD). ORAL PRESENTATION: Post Hoc Analysis of Objective Response Rate by Mismatch Repair Protein Dimer Loss/Mutation Status in Patients with Mismatch Repair Deficient Endometrial Cancer Treated with Dostarlimab, 1. Modeling of short-acting beta agonist (SABA) use: effect of symptom control in patients with moderate-severe asthma requiring rescue medication.